Hepatitis B vaccination of newborns in rural China: evaluation of an out-of-coldchain delivery strategy Istanbul, Turkey March 15-17, 2006
Contents Introduction Objective Methods and Implementation Results Conclusions Next steps
Hepatitis B in China Hepatitis B (HB) is one of the four major infectious diseases in China 120 million people are chronically infected with hepatitis B virus (HBV) 10% of the population An estimated 280,000 deaths annually >33% of global deaths attributed to HB Sources: State of the World s Vaccines and Immunization. WHO, UNICEF, The World Bank. 2002. The Global Alliance for Vaccines and Immunization. Progress Report. 2002. 1992 National Serosurvey. China.
HBV surface antigen rate among children Rural: 28% HBsAg Rate 12% 10% 8% 6% 4% 7.12% Urban 1992 Urban: 71% 2.10% 11.40% Rural 1992 Rural 2002 8.25% 2% 0% Urban 2002 Source: Serosurvey adopting the samples from 2002 national nutrition survey (unpublished)
Increase in on-time administration of HB vaccine birth dose Coverage(%) 100 90 80 70 60 50 40 30 20 10 0 National Eastern Middle Western 1997 2001 2002 2003 Project Focus Source: National EPI Coverage Survey. China. 1999 and 2004
Proportion of children receiving the HB vaccine birth dose on 1st or 2nd day of life Overall Geography Mountains Hills Plains Project Focus Place of Birth Home Township Hospital County Hospital or Above 0 10 20 30 40 50 60 70 80 90 Percent (Weighted) Source: National EPI Coverage Survey. China. 1999
Objective To evaluate strategies for improving on-time delivery (within 24 hours) of the HB vaccine birth dose in remote areas of China, especially among children born at home.
Study design Townships situated at least 20 km from the county capital in three counties in Hunan Province were randomly divided into three groups: Group 1: Ampoule inside the cold chain Group 2: Ampoule outside the cold chain Group 3: HB vaccine in Uniject * (HB-Uniject) outside the cold chain All ampoules of HB vaccine and HB-Uniject packages were marked with vaccine vial monitors (VVMs) *Uniject is a registered trademark of BD.
Hospital vaccination in the cold chain; home vaccination out of the cold chain Group 1: HB vaccine delivered in township hospitals. Vaccine stored in the cold chain Group 2 and Group 3: Village-based doctors and midwives trained as vaccine providers. Vaccine stored and delivered out of the cold chain
Preparations Held trainings with vaccine providers at township and village levels Conducted social mobilization to emphasize the importance of hepatitis B immunization and on-time delivery of the birth dose Monitored vaccine storage temperatures with data loggers
Evaluation methods Baseline and final coverage survey Review of children s immunization cards Review of village/township immunization records Immunologic response survey Radioimmunoassay for HBsAg, anti-hbs
Results: Significant improvements in on-time vaccination Percent of infants who received the first dose of vaccine within 24 hours of birth 100 Raising awareness helps 80 60 40 20 0 8.0 57.9 Group 1: Ampoule Inside Cold Chain Out-of-coldchain storage helps more 11.3 67.8 Group 2: Ampoule Outside Cold Chain 6.8 Uniject helps even more 77.3 Group 3: HB-Uniject Outside Cold Chain 8.7 Baseline Final Total 67.6
Results: Significant improvements in on-time vaccination Hospital births improved Home births improved by by raising awareness out-of-cold-chain strategy Percent of infants who received the first dose of vaccine within 24 hours of birth 100 80 60 40 20 0 11.0 Born in the hospital 87.6 77.9 80.3 Group 1 Ampoule Inside Cold Chain 18.4 Group 2 Ampoule Outside Cold Chain 10.7 Group 3 HB- Uniject Outside Cold Chain 25.2 51.8 2.4 2.5 0.6 Group 1 Ampoule Inside Cold Chain Born at home Group 2 Ampoule Outside Cold Chain Baseline Final 66.7 Group 3 HB- Uniject Outside Cold Chain
Results: Home-born infants better served when vaccinated at home 100 80 60 40 20 0 73.5 Home-born and immunized at home 32.8 Home-born and immunized in township hospital Percent of infants who received the first dose of vaccine within 24 hours of birth
Serology results: No difference between inthe-cold-chain and out-of-cold-chain groups Groups Children observed Anti-HBs positive HBsAg positive Children % 95%CI Children % 95%CI Group 1 203 194 95.6 91.5-97.8 1 0.5 0.03-3.1 Group 2 203 195 96.1 92.1-98.2 1 0.5 0.03-3.1 Group 3 200 191 95.5 91.4-97.8 3 1.5 0.4-4.7 Total 606 580 96.0 93.7-97.1 5 0.8 0.3-2.0
Serology results: No difference between inthe-cold-chain and out-of-cold-chain groups Groups Children observed Children with Anti- HBs + Group 1 203 194 Group 2 203 195 Group 3 200 191 Anti-HBs>=10 miu/ml Among Anti- HBs positive (%) 180 (92.8 %) 184 (94.4 %) 178 (93.2 %) Among children observed (%) 180 (88.7 %) 184 (90.6 %) 178 (89.0 %) GMT 95.5 93.3 102.3 Inside cold chain 203 194 180 (92.8 %) 180 (88.7 %) 95.5 Outside cold chain 403 386 362 (93.8 %) 362 (89.8 %) 97.7 Total 606 580 542 (93.5 %) 542 (89.4 %) 97.7
Storage temperatures: freeze and heat exposure In the cold chain: 2/3 township refrigerators below 0 C Out of the cold chain: temperatures 2 C 30 C 0.2% vaccine was discarded due to heat exposure VVMs effective in identifying heat exposure No serious adverse events following immunization were reported during the study
Acceptability of Uniject Among providers who had used the Uniject device: 98% thought Uniject was easy to carry, transport, and use 95% thought Uniject could administer a full dose of HB vaccine 88% thought Uniject could save immunization time compared with standard syringes Almost all immunization providers thought that the village-based out-of-cold-chain strategy could improve the on-time delivery of the HB vaccine birth dose among children born at home
Conclusion 1 In remote areas in China and other countries where many children are born at home, on-time administration of HB vaccine has been difficult to achieve through routine immunization service Village health workers using an out-of-cold chain immunization strategy can improve the on-time administration of the HB vaccine birth dose among infants born at home Training and monitoring of hospital health workers can improve on-time administration of the HB vaccine birth dose to children born in hospitals
Conclusion 2 Simple tools such as VVMs and Uniject can ensure vaccine quality and injection safety when vaccines are administered by village health workers HB vaccine is sufficiently heat stable to withstand routine out-of-cold-chain storage in tropical conditions without loss of immunogenicity Taking vaccine out of the cold chain could potentially decrease the risk of vaccine damage due to inadvertent freezing
Next steps Improve awareness and coordination of the birth dose in hospital settings through increased supervision HB vaccine manufacturer will start application of licensure for use of HB-Uniject stored out of the cold chain Introduce VVMs on EPI vaccines, in accordance with UNICEF and WHO recommendations Adopt national policy of HB vaccine storage out of the cold chain, initially in warm areas among children born at home
Lixia Wang, MD Program Officer Immunization Solutions Strategic Program PATH lwang@path.org www.path.org
Increase in coverage of HB3 Coverage(%) 100 90 80 70 60 50 40 30 20 10 0 Integration into EPI since 2002 National Beijing Hubei Guizhou 2001 2002 2003 Source: National Coverage Survey, 2004
Progress in Hepatitis B Immunization Western Provinces 1999-2004 * 4000 Doses Administered (1000s) 3500 3000 2500 2000 1500 1000 500 BCG DTP1 DTP3 HBV1 HBV3 HBV1 Ontime 0 1999 2000 2001 2002 2003 2004 * Adjusted for corrected data Qinghai (2004), Xinjiang (2003-4)